Novo Nordisk A/S confirms Saxenda (liraglutide) for the treatment of obesity received positive 14-1 vote in favor of approval from FDA Advisory Committee
Co announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA has completed its meeting regarding the New Drug Application for Saxenda, the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue for the treatment of obesity.